IDEXX Laboratories stock heads toward November 2 results

Published on 10/04/2026 at 12:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock was last at USD 518.39 on October 2, 2026, while Q2 EPS reached USD 4.27 versus USD 3.94 consensus. Q3 results are scheduled for November 2.

Makro: Diagnostischer Teststreifen mit lila Reaktionslinien in Petrischale, Teal-Bokeh — IDEXX Laboratories US45168D1046 Makro Aufnahme eines Diagnosetest Streifens mit Reaktionslinien in einer Petrischale, Illustration mit AI erstellt.

IDEXX Laboratories (ISIN US45168D1046) was last at USD 518.39 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a daily gain of 0.12 percent from USD 517.75. The next company checkpoint is the Q3 2026 results release scheduled for November 2, 2026, according to FT on October 1, 2026.

November 2 sets the next test

The scheduled release gives investors a clear date for the next update on diagnostic demand, recurring revenue and margin performance. The company will hold its earnings call at 8:30 a.m. ET on the same date, with results due before the market opens, the announcement said.

Q2 EPS beat consensus by USD 0.33

IDEXX reported Q2 2026 revenue of USD 1.22 billion, up 9.7 percent from the prior-year quarter, while adjusted EPS reached USD 4.27 against consensus of USD 3.94, according to MarketBeat in its September 10, 2026 report. The same report lists fiscal 2026 adjusted EPS guidance of USD 14.690-14.940, placing the Q2 result against a full-year framework.

The earnings comparison is the central operating signal: EPS exceeded consensus by USD 0.33, while revenue growth remained positive on a year-over-year basis. For investors, the November release will show whether that earnings conversion continues into the second half of fiscal 2026.

Analysts see USD 747.00 target

MarketBeat reports a Moderate Buy consensus based on six Buy ratings and four Holds, with an average 12-month price target of USD 747.00. Barclays lowered its target from USD 800.00 to USD 710.00 while retaining an Overweight rating on August 11, 2026, illustrating the gap between the broader consensus and individual target revisions.

Stock remains below its yearly high

IDEXX Laboratories stock was last at USD 518.39 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with volume of 287,828 shares. Its 52-week range was USD 500.61 to USD 769.98, leaving the reference price 32.7 percent below the high; market capitalization stood at USD 40.9 billion.